AVI BioPharma CEO to Present at Fifth Annual Rodman & Renshaw Techvest Healthcare Conference
PORTLAND, Ore. - Oct. 20, 2003 - AVI BioPharma, Inc. (Nasdaq: AVII), today announced that the company is scheduled to present at the fifth annual Rodman & Renshaw Techvest Healthcare Conference at the Boston Marriott Long Wharf Hotel.
Denis R. Burger, Ph.D., chief executive officer of AVI, is scheduled to speak at 10:30 a.m. EDT on Tuesday, Oct. 21. Burger will present an update on AVI's clinical development programs, including those related to cardiovascular disease, antiviral applications and cancer.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NeuGene® antisense drugs and cancer immunotherapy. AVI's lead NeuGene antisense compound is designed to target cardiovascular restenosis, cancer, polycystic kidney disease and other cell proliferation disorders. In addition to targeting specific genes in the body, AVI's antiviral program uses NeuGene antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVI's second technology, Avicine®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic and colorectal cancer. More information about AVI is available on the company's Web site at http://www.avibio.com/.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings.